Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr733 Inhibitors

Olr733 inhibitors represent a fascinating class of chemical compounds that are primarily studied for their role in modulating the activity of the Olr733 receptor. The Olr733 receptor, belonging to the olfactory receptor family, is a G protein-coupled receptor (GPCR) that plays a significant role in the chemosensory system, specifically in the detection of odor molecules. These inhibitors are characterized by their ability to bind to the Olr733 receptor, thereby altering its conformation and preventing it from interacting with its natural ligands. This interaction is crucial for understanding how olfactory signals are modulated at the molecular level. The study of Olr733 inhibitors involves a variety of approaches, including computational modeling, structure-activity relationship (SAR) analysis, and in vitro assays, to elucidate their binding mechanisms and efficacy.

Structurally, Olr733 inhibitors can vary widely, but they typically possess features that enable them to interact specifically with the binding sites of the Olr733 receptor. This specificity is often achieved through the presence of hydrophobic moieties, aromatic rings, and hydrogen bond donors and acceptors that complement the receptor's active site. Advanced analytical techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to characterize the binding interactions at an atomic level, providing insights into the molecular dynamics of these inhibitors. Additionally, the synthesis of Olr733 inhibitors involves intricate organic chemistry processes that aim to optimize their potency and selectivity. By studying these compounds, researchers gain a deeper understanding of the olfactory signaling pathways and the molecular intricacies of receptor-ligand interactions, contributing to the broader field of sensory biology and receptor pharmacology.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, potentially disrupts MAPK/ERK signaling, affecting cell proliferation and survival.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, potentially affects NF-kB signaling and induces apoptosis in cancer cells.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

BCR-ABL tyrosine kinase inhibitor, potentially disrupts abnormal protein signaling in chronic myeloid leukemia.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, potentially inhibits cytokine signaling involved in myeloproliferative disorders.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, potentially inhibits angiogenesis and tumor cell proliferation.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$111.00
$357.00
8
(0)

Immunomodulatory drug, potentially disrupts TNF-alpha production and angiogenesis.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

MET, VEGFR2, and RET inhibitor, potentially affects tumor growth and angiogenic pathways.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Multi-targeted tyrosine kinase inhibitor, potentially inhibits VEGFR and other growth factor receptors.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially disrupts cell cycle progression in breast cancer.